AR063

AR063 is a preclinical-stage therapeutic candidate being developed by Y Biologics for the treatment of solid tumors. It utilizes a Degrader-Antibody Conjugate (DAC) modality, which typically involves the conjugation of a monoclonal antibody to a targeted protein degrader payload. This approach aims to combine the precise targeting of antibodies with the potent intracellular protein-clearing capabilities of degraders, potentially offering a more selective therapeutic effect and improved therapeutic index compared to systemic protein degraders. As of the current pipeline status, the specific molecular target and the nature of the degrader payload for AR063 have not been publicly disclosed.